BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi W, Sun Q, Zhang S, Hu J, Xu H. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol 2018;11:102. [PMID: 30103775 DOI: 10.1186/s13045-018-0646-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Ni H, Lu Z, Huang X, Ning S, Liang X, Zhang S, Xiang B. Combining Pre- and Postoperative Lymphocyte–C-Reactive Protein Ratios Can Better Predict Hepatocellular Carcinoma Prognosis After Partial Hepatectomy. JIR 2022;Volume 15:2229-41. [DOI: 10.2147/jir.s359498] [Reference Citation Analysis]
2 Azizi AA, Pillai M, Thistlethwaite FC. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. Curr Opin Oncol 2019;31:430-8. [PMID: 31335828 DOI: 10.1097/CCO.0000000000000562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Cui X, Liu R, Duan L, Cao D, Zhang Q, Zhang A. CAR-T therapy: Prospects in targeting cancer stem cells. J Cell Mol Med 2021;25:9891-904. [PMID: 34585512 DOI: 10.1111/jcmm.16939] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Morandi F, Sabatini F, Podestà M, Airoldi I. Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future. Vaccines (Basel) 2021;9:43. [PMID: 33450862 DOI: 10.3390/vaccines9010043] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zeng XX, Zeng J, Zhu B. Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control. Rev Neurosci 2021. [PMID: 34529907 DOI: 10.1515/revneuro-2021-0068] [Reference Citation Analysis]
6 Kang L, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Fu C, Tang X, Dai H, Chen J, Wu D, Yu L. Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. Biomark Res 2020;8:14. [PMID: 32435496 DOI: 10.1186/s40364-020-00192-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 Li T, Li H, Li S, Xu S, Zhang W, Gao H, Xu H, Wu C, Wang W, Yu X, Liu L. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Cancer Med 2019;8:5223-31. [PMID: 31339230 DOI: 10.1002/cam4.2430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Sur D, Havasi A, Cainap C, Samasca G, Burz C, Balacescu O, Lupan I, Deleanu D, AlexandruIrimie. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J Clin Med 2020;9:E182. [PMID: 31936611 DOI: 10.3390/jcm9010182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
9 Fu R, Li H, Li R, Mcgrath K, Dotti G, Gu Z. Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors. Adv Funct Mater 2021;31:2009489. [DOI: 10.1002/adfm.202009489] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
10 Yeo D, Giardina C, Saxena P, Rasko JEJ. The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics 2022;24:561-76. [PMID: 35229033 DOI: 10.1016/j.omto.2022.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Wu M, Yang S, Feng X, Li C, Liu X, Zhang Z, Xiao Y, Liu C, Dong J. Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy. J Inflamm Res 2021;14:3231-45. [PMID: 34285546 DOI: 10.2147/JIR.S316177] [Reference Citation Analysis]
12 Lu P, Hill HA, Navsaria LJ, Wang ML. CAR-T and other adoptive cell therapies for B cell malignancies. Journal of the National Cancer Center 2021;1:88-96. [DOI: 10.1016/j.jncc.2021.07.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174. [PMID: 30917934 DOI: 10.1016/j.redox.2019.101174] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 19.0] [Reference Citation Analysis]
14 Chen L, Chen F, Li J, Pu Y, Yang C, Wang Y, Lei Y, Huang Y. CAR-T cell therapy for lung cancer: Potential and perspective. Thorac Cancer 2022. [PMID: 35289077 DOI: 10.1111/1759-7714.14375] [Reference Citation Analysis]
15 Wang D, Feng W, Wang X, Lin D, Wang X, Guo X, Miao Q, Ma J, Xia G. Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle. Eur J Pharm Sci 2021;167:106000. [PMID: 34517105 DOI: 10.1016/j.ejps.2021.106000] [Reference Citation Analysis]
16 Di Roberto RB, Castellanos-Rueda R, Frey S, Egli D, Vazquez-Lombardi R, Kapetanovic E, Kucharczyk J, Reddy ST. A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. Mol Ther 2020;28:2564-76. [PMID: 32827460 DOI: 10.1016/j.ymthe.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Mhaidly R, Verhoeyen E. Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies. Cancers (Basel) 2020;12:E1915. [PMID: 32679920 DOI: 10.3390/cancers12071915] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
18 Liu K, Cui J, Zhan Y, Ouyang Q, Lu Q, Yang D, Li X, Yin J. Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01561-5] [Reference Citation Analysis]
19 Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther 2021;21:473-86. [PMID: 33176519 DOI: 10.1080/14712598.2021.1843628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
20 Yang P, Wang Y, Yao Z, Gao X, Liu C, Wang X, Wu H, Ding X, Hu J, Lin B, Li Q, Li M, Li X, Chen X, Qi W, Li W, Xue J, Xu H. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. J Am Chem Soc 2020;142:18874-85. [DOI: 10.1021/jacs.0c08538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Li H, Yang C, Cheng H, Huang S, Zheng Y. CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. J Cancer 2021;12:1804-14. [PMID: 33613769 DOI: 10.7150/jca.50509] [Reference Citation Analysis]
22 Sahlolbei M, Dehghani M, Kheiri Yeghane Azar B, Vafaei S, Roviello G, D'Angelo A, Madjd Z, Kiani J. Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. Int Rev Immunol 2020;39:223-32. [PMID: 32546036 DOI: 10.1080/08830185.2020.1776274] [Reference Citation Analysis]
23 Zhao Y, Zhou X. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy. Immunotherapy 2020;12:653-64. [DOI: 10.2217/imt-2019-0139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
25 Date V, Nair S. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert Opin Biol Ther 2021;21:145-60. [PMID: 32882159 DOI: 10.1080/14712598.2020.1819978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 2020;13:130. [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
27 Liao Q, Mao Y, He H, Ding X, Zhang X, Xu J. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo. Biomark Res 2020;8:57. [PMID: 33292688 DOI: 10.1186/s40364-020-00237-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Miao L, Zhang Z, Ren Z, Li Y. Reactions Related to CAR-T Cell Therapy. Front Immunol 2021;12:663201. [PMID: 33995389 DOI: 10.3389/fimmu.2021.663201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lv J, Li P. Mesothelin as a biomarker for targeted therapy. Biomark Res 2019;7:18. [PMID: 31463062 DOI: 10.1186/s40364-019-0169-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
30 Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Front Immunol 2020;11:888. [PMID: 32477359 DOI: 10.3389/fimmu.2020.00888] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
31 Caliendo F, Dukhinova M, Siciliano V. Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology. Front Bioeng Biotechnol 2019;7:43. [PMID: 30937303 DOI: 10.3389/fbioe.2019.00043] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]